{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:10:02Z","timestamp":1791943802935,"version":"4.3.4"},"reference-count":23,"publisher":"Society of Nuclear Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,10,28]]},"published-print":{"date-parts":[[2026,2]]},"DOI":"10.2967\/jnumed.125.270916","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:40:20Z","timestamp":1764866420000},"page":"246-252","source":"Crossref","is-referenced-by-count":5,"title":["Linking Baseline PSMA PETDerived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [\n                    <sup>177<\/sup>\n                    Lu]Lu-PSMA-617: A Single-Center Retrospective Study"],"prefix":"10.2967","volume":"67","author":[{"given":"Vishnu","family":"Murthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lela","family":"Theus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan R.","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ojaswita","family":"Lokre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Perk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Rettig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Drakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Thin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rejah Marie","family":"Nabong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Gafita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Czernin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Calais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"2026020205350892000_67.2.246.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026020205350892000_67.2.246.2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","article-title":"Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Fizazi","year":"2023","journal-title":"Lancet Oncol."},{"key":"2026020205350892000_67.2.246.3","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet."},{"key":"2026020205350892000_67.2.246.4","doi-asserted-by":"crossref","first-page":"S964","DOI":"10.1016\/j.annonc.2024.08.1680","article-title":"Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: third interim analysis of PSMAfore","volume":"35","author":"Fizazi","year":"2024","journal-title":"Ann Oncol."},{"key":"2026020205350892000_67.2.246.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268818"},{"key":"2026020205350892000_67.2.246.6","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.1200\/JCO.2024.42.16_suppl.5075","article-title":"Hematologic toxicity in 177Lu-PSMA-617 treatment for mCRPC: unraveling the impact of PSMA PET bone tumor volume (PSMA-bTTV)","volume":"42(suppl)","author":"Ghodsi","year":"2024","journal-title":"J Clin Oncol."},{"key":"2026020205350892000_67.2.246.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06255-8"},{"key":"2026020205350892000_67.2.246.8","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026020205350892000_67.2.246.9","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460"},{"key":"2026020205350892000_67.2.246.10","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1200\/JCO.2025.43.16_suppl.5079","article-title":"Assessment of PSMA PET\/CT derived predictive markers for 177Lu-PSMA-617 treatment outcomes: results from the U.S. expanded-access program","volume":"43","author":"Kimura","year":"2025","journal-title":"J Clin Oncol."},{"key":"2026020205350892000_67.2.246.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267816"},{"key":"2026020205350892000_67.2.246.12","first-page":"171","article-title":"Retina U-Net: embarrassingly simple exploitation of segmentation supervision for medical object detection","volume":"116","author":"Jaeger","year":"2020","journal-title":"Proc Mach Learn Res."},{"key":"2026020205350892000_67.2.246.13","first-page":"3215","article-title":"Automated detection and quantification of neuroendocrine tumors on 68Ga-DOTATATE PET\/CT images using a U-Net ensemble method","volume":"63(suppl)","author":"Weisman","year":"2022","journal-title":"J Nucl Med."},{"key":"2026020205350892000_67.2.246.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00459-7"},{"key":"2026020205350892000_67.2.246.15","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singap."},{"key":"2026020205350892000_67.2.246.16","first-page":"12","article-title":"The xerostomia inventory: a multi-item approach to measuring dry mouth","volume":"16","author":"Thomson","year":"1999","journal-title":"Community Dent Health."},{"key":"2026020205350892000_67.2.246.17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13550-021-00805-7","article-title":"Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"11","author":"Groener","year":"2021","journal-title":"EJNMMI Res."},{"key":"2026020205350892000_67.2.246.18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13550-022-00891-1","article-title":"Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: haematotoxicity or tumour progression?","volume":"12","author":"Kind","year":"2022","journal-title":"EJNMMI Res."},{"key":"2026020205350892000_67.2.246.19","first-page":"241590","article-title":"Effect of bone marrow disease on hematologic toxicity and PSA response to 177Lu-PSMA-617 therapy [abstract]","volume":"65(suppl 2)","author":"Losee","year":"2024","journal-title":"J Nucl Med."},{"key":"2026020205350892000_67.2.246.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2026020205350892000_67.2.246.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265077"},{"key":"2026020205350892000_67.2.246.22","unstructured":"Hofman MS Emmett L Sandhu S . Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2023;25:99107."},{"key":"2026020205350892000_67.2.246.23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:18:22Z","timestamp":1785269902000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,2]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.2967\/jnumed.125.270916"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270916","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]}}}